MakeMyTrip
MMYT · NASDAQ
About MMYT
- Employees
- 5,122
- Headquarters
- Gurgaon, Haryana
- Listed
- Aug 12, 2010
- Sector
- Consumer Discretionary
- Industry
- Hotels, Restaurants & Leisure
- Website
- investors.makemytrip.com
MMYT key statistics
- Market cap
- 4.32B
- Price-earnings ratio
- 222.60
- Dividend yield
- —
- Average volume
- 1.23M
- Volume
- 947.82K
- Open price
- $44.51
- High today
- $46.54
- Low today
- $43.99
- 52 Week high
- $92.09
- 52 Week low
- $32.67
MakeMyTrip (MMYT) at a glance
MakeMyTrip (MMYT) last traded at $45.91, with a market cap of 4.32B and a price-to-earnings ratio of 222.60.
Today the stock has traded between $43.99 and $46.54. The current price is 4.4% above the day's low and 1.4% below its high.
Volume so far is 947.82K shares, below the average of 1.23M shares a day.
Over the past year MakeMyTrip has ranged from $32.67 to $92.09, and now sits 22% of the way up that range.
MakeMyTrip met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q1 FY27 it reported $0.53 per share against an estimate of $0.461.
The average analyst price target is $76.38, 66.4% above the current price, from 3 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
- Buy100.0%
- Hold0.0%
- Sell0.0%
- Low
- $60.60
- Now
- $45.91
- High
- $89.25
MMYT earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 6 of the last 8 quarters, by 20.2% on average.
- Q2 FY25: reported $0.36 per share against an estimate of $0.2652
- Q3 FY25: reported $0.35 per share against an estimate of $0.3284
- Q4 FY25: reported $0.42 per share against an estimate of $0.307
- Q1 FY26: reported $0.42 per share against an estimate of $0.3764
- Q2 FY26: reported $0.37 per share against an estimate of $0.3203
- Q3 FY26: reported $0.39 per share against an estimate of $0.3978
- Q4 FY26: reported $0.32 per share against an estimate of $0.3468
- Q1 FY27: reported $0.53 per share against an estimate of $0.461
MMYT news
- Press releaseBusiness Wire
MakeMyTrip Q1 2027 Earnings Call Transcript
- Avi Kapoor
Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock
- Press releaseBusiness Wire
MakeMyTrip Limited to Report Fiscal 2027 First Quarter Financial & Operating Results on August 03, 2026
- Press releaseBusiness Wire
MakeMyTrip Limited to Report Fiscal 2026 Fourth Quarter and Full Year Financial & Operating Results on May 19, 2026
- Press releasePRNewswire
Trip.com Group Limited Reports Unaudited Fourth Quarter and Full Year of 2025 Financial Results
- Press releaseBusiness Wire
MakeMyTrip Deepens AI-First Strategy with OpenAI Collaboration
Examining the Future: MakeMyTrip's Earnings Outlook
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.